CHARLOTTESVILLE, Va. and CARMEL, Ind., July 16, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that ...
Acumen Pharmaceuticals (ABOS) targets a novel mechanism hypothesized as responsible for Alzheimer's. Lead candidate ACU193 is a monoclonal antibody that selectively targets Amyloid-beta oligomers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results